Nycomed submits ultrasound contrast NDA

Article

Contrast agent developer Nycomed Amersham hopes soon to join the ultrasound contrast race. The Buckingham, U.K.-based firm has submitted a new drug application (NDA) to the Food and Drug Administration for Sonazoid, an ultrasound contrast agent formerly

Contrast agent developer Nycomed Amersham hopes soon to join the ultrasound contrast race. The Buckingham, U.K.-based firm has submitted a new drug application (NDA) to the Food and Drug Administration for Sonazoid, an ultrasound contrast agent formerly called NC100100. In support of its application, Nycomed has submitted clinical data demonstrating echocardiographic improvement in endocardial border delineation and left ventricular opacification when Sonazoid is used. Nycomed performed clinical trials for the agent on approximately 1300 patients in Europe and the U.S.

Nycomed has been defending patents covering the agent’s technology since 1997, when it became embroiled in a dispute with San Diego-based Molecular Biosystems and St. Louis-based Mallinckrodt (SCAN 4/29/98).

Developed for use in such cardiology and radiology applications as heart and liver imaging, Sonazoid is also being investigated for use in imaging myocardial perfusion. The company’s Japanese partner in ultrasound contrast agent R&D, Daiichi Pharmaceutical, has completed phase I trials for liver and heart imaging applications for Sonazoid. Nycomed plans to submit an equivalent clearance document for the agent in Europe later this year.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound

What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound

Jeff Hall
April 4th 2025
Article

In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.

The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET

The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET

Jeff Hall
March 18th 2025
Podcast

In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.

Self-Interpretation of Imaging by Non-Radiologists Accounts for 43.5 Percent of Medicare Imaging Claims

Self-Interpretation of Imaging by Non-Radiologists Accounts for 43.5 Percent of Medicare Imaging Claims

Jeff Hall
April 3rd 2025
Article

In a review of over 1,630,000 office-based non-breast imaging Medicare fee-for-service (FFS) claims from 2022, researchers found that 39.5 percent of nuclear medicine imaging were interpreted by ordering clinicians.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

Jeff Hall
September 1st 2023
Podcast

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men

Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men

Jeff Hall
April 3rd 2025
Article

After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.

GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference

GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference

Jeff Hall
April 1st 2025
Article

Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.

© 2025 MJH Life Sciences

All rights reserved.